|
1. Montague Z, Lv H, Otwinowski J, DeWitt WS, Isacchini G, Yip GK, Ng WW, Tsang OT, Yuan M, Liu H, Wilson IA, Peiris M, Wu NC, Nourmohammad A, Mok CKP. (2021) Dynamics of B-cell repertoires and emergence of cross-reactive responses in COVID-19 patients with different disease severity. Cell Reports. In press.
|
|
2. Arunachalam PS*, Wimmers F*, Mok CKP*, Perera M*, Scott M, Hagan T, Sigal N, Feng Y, Bristow L, Tsang OT, Wagh D, Coller J, Pellegrini KL, Kazmin D, Alaaeddine G, Leung WS, Chan JMC, Chik TSH, Choi CYC, Huerta C, McCullough MP, Lv H, Anderson E, Edupuganti S, Upadhyay AA, Bosinger SE, Maecker HT, Khatri P, Rouphael N, Peiris M, Pulendran B. (2020) Systems biological assessment of immunity to severe and mild COVID-19 infections. Science. 369:1210-1220. (*co-first authors).
|
|
3. Yuan M, Wu NC, Zhu X, Lee CCD, So RTY, Lv H, Mok CKP*, Wilson IA* (2020) A highly conserved cryptic epitope in the receptor-binding 4 domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633 (*co-corresponding authors).
|
|
4. Mok CKP, Zhu A, Zhao J, Lau EHY, Wang J, Chen Z, Zhuang Z, Wang Y, Wang W, Tan W, Liang W, Oladipo JO, Kuranga SA, Peiris M, Zhao J (2020) Specific T cell responses provide evidence of MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria. Lancet Infect Dis 6:S1473-3099(20)30599-5.
|
|
5. Hachim A, Kavian N, Cohen CA, Chin AWH, Chu DKW, Mok CKP, Tsang OTY, Yeung YC, Perera RAPM, Poon LLM, Peiris JSM, Valkenburg SA (2020) ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat Immunol. 21(10):1293-1301
|
6. Lv H, Wu NC, Tsang OT, Yuan M, Perera RAP, Leung WS, So RT, Chan JMC, Yip GK, Chik TSH, Wang Y, Choi CYC, Lin Y, Ng WW, Zhao J, Poon LLM, Peiris JSM, Wilson IA, Mok CKP (2020) Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep, 31(9):107725.
|
7. Wu NC, Lv H, Thompson AJ, Wu DC, Ng WWS, Kadam RU, Lin CW, Nycholat CM, McBride R, Liang W, Paulson JC, Mok CKP*, Wilson IA* (2019) Preventing an antigenically disruptive mutation in egg-based H3N2 seasonal influenza vaccines by mutational incompatibility. Cell Host Microbe 25:836-844 (*co-corresponding authors).
|
8. Guan W, Wu NC, Lee HHY, Li Y, Jiang W, Shen L, Wu DC, Chen R, Zhong N, Wilson IA, Peiris M, Yang Z, Mok CK (2018) Clinical correlations of transcriptional profile in patients infected with avian influenza H7N9 Virus. J Infect Dis 218:1238-1248.
|
9. Ke C*, Mok CKP*, Zhu W*, Zhou H, He J, Guan W, Wu J, Song W, Wang D, Liu J, Lin Q, Chu DKW, Yang L, Zhong N, Yang Z, Shu Y, Peiris JSM (2017) Human infection with highly pathogenic avian influenza A(H7N9) virus, China. Emerg Infect Dis 23:1332-1340 (*co-first author).
|
10. Yang ZF*, Mok CK*, Peiris JSM, Zhong NS (2015) Human infection with a novel avian influenza A(H5N6) virus. N Engl J Med 373:487-489 (*co-first author).
|
11. Chan MC*, Chan RW*, Chan LL*, Mok CK*, Hui KPY, Fong JHM, Tao KP, Poon LL, Nicholls JM, Guan Y, Peiris JS (2013) Tropism and innate host responses of a novel avian origin influenza A (H7N9) virus in ex vivo and in vitro cultures of the human respiratory tract. Lancet Resp Med 1:534-542 (*co-first author).
|